Recursion Pharmaceuticals, Inc.
RXRX
$3.39
-$0.03-0.88%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 74.68M | 43.69M | 64.60M | 59.79M | 58.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 74.68M | 43.69M | 64.60M | 59.79M | 58.84M |
| Cost of Revenue | 546.22M | 547.14M | 498.07M | 432.40M | 359.66M |
| Gross Profit | -471.54M | -503.45M | -433.47M | -372.61M | -300.82M |
| SG&A Expenses | 185.10M | 220.12M | 216.25M | 201.43M | 178.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 731.33M | 767.25M | 714.31M | 633.82M | 537.84M |
| Operating Income | -656.65M | -723.57M | -649.72M | -574.03M | -479.01M |
| Income Before Tax | -644.89M | -715.69M | -649.12M | -575.28M | -464.79M |
| Income Tax Expenses | -135.00K | -148.00K | 16.00K | -507.00K | -1.13M |
| Earnings from Continuing Operations | -644.76 | -715.54 | -649.13 | -574.78 | -463.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -644.76M | -715.54M | -649.13M | -574.78M | -463.66M |
| EBIT | -656.65M | -723.57M | -649.72M | -574.03M | -479.01M |
| EBITDA | -572.95M | -646.39M | -586.39M | -525.59M | -442.51M |
| EPS Basic | -1.48 | -1.81 | -1.79 | -1.78 | -1.66 |
| Normalized Basic EPS | -0.94 | -1.13 | -1.12 | -1.11 | -1.04 |
| EPS Diluted | -1.48 | -1.81 | -1.79 | -1.78 | -1.66 |
| Normalized Diluted EPS | -0.94 | -1.13 | -1.12 | -1.11 | -1.04 |
| Average Basic Shares Outstanding | 1.79B | 1.60B | 1.44B | 1.26B | 1.10B |
| Average Diluted Shares Outstanding | 1.79B | 1.60B | 1.44B | 1.26B | 1.10B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |